FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2886521817> ?p ?o ?g. }

• W2886521817 endingPage "537" @default.
• W2886521817 startingPage "530" @default.
• W2886521817 abstract "This open-label phase III trial evaluated efficacy and safety of S-1 plus cisplatin vs. cisplatin alone as first-line chemotherapy in patients with stage IVB, recurrent, or persistent cervical cancer. Patients were randomised (1:1) to S-1 plus cisplatin (study group) or cisplatin alone (control group). In each cycle, cisplatin 50 mg/m2 was administered on Day 1 in both groups. S-1 was administered orally at 80–120 mg daily on Days 1–14 of a 21-day cycle in the study group. The primary endpoint was overall survival (OS). A total of 375 patients were enrolled, of whom 364 (188, study group; 176, control group) received treatment. Median OS was 21.9 and 19.5 months in the study and control groups, respectively (log-rank P = 0.125; hazard ratio [HR] 0.84, 95% confidence interval [CI] 0.67–1.05). Median progression-free survival (PFS) was 7.3 and 4.9 months in the study and control groups, respectively (HR 0.62, 95% CI 0.48–0.80, P < 0.001). The adverse event (AE) rate increased in the study group despite the absence of any unexpected AEs. S-1 plus cisplatin did not show superiority over cisplatin alone in OS but significantly increased PFS in patients with stage IVB, recurrent, or persistent cervical cancer. Since the standard therapy has changed in the course of this study, further studies are warranted to confirm the clinical positioning of S-1 combined with cisplatin for this population." @default.
• W2886521817 created "2018-08-22" @default.
• W2886521817 creator A5003303543 @default.
• W2886521817 creator A5004341345 @default.
• W2886521817 creator A5004971708 @default.
• W2886521817 creator A5010889533 @default.
• W2886521817 creator A5013129858 @default.
• W2886521817 creator A5013258133 @default.
• W2886521817 creator A5015274805 @default.
• W2886521817 creator A5023832239 @default.
• W2886521817 creator A5025092869 @default.
• W2886521817 creator A5025271372 @default.
• W2886521817 creator A5042172035 @default.
• W2886521817 creator A5045026176 @default.
• W2886521817 creator A5047438296 @default.
• W2886521817 creator A5050726729 @default.
• W2886521817 creator A5053997136 @default.
• W2886521817 creator A5054188737 @default.
• W2886521817 creator A5054335379 @default.
• W2886521817 creator A5070805573 @default.
• W2886521817 creator A5076136934 @default.
• W2886521817 creator A5084956582 @default.
• W2886521817 date "2018-08-01" @default.
• W2886521817 modified "2023-10-07" @default.
• W2886521817 title "Phase III study of cisplatin with or without S-1 in patients with stage IVB, recurrent, or persistent cervical cancer" @default.
• W2886521817 cites W1857980043 @default.
• W2886521817 cites W1926137745 @default.
• W2886521817 cites W1932754573 @default.
• W2886521817 cites W2018593099 @default.
• W2886521817 cites W2035200579 @default.
• W2886521817 cites W2045849258 @default.
• W2886521817 cites W2100756525 @default.
• W2886521817 cites W2118508302 @default.
• W2886521817 cites W2126768246 @default.
• W2886521817 cites W2126834211 @default.
• W2886521817 cites W2129763891 @default.
• W2886521817 cites W2138550445 @default.
• W2886521817 cites W2139248078 @default.
• W2886521817 cites W2148287035 @default.
• W2886521817 cites W2158679766 @default.
• W2886521817 cites W2169043777 @default.
• W2886521817 cites W2171075804 @default.
• W2886521817 cites W2171725862 @default.
• W2886521817 cites W2397841699 @default.
• W2886521817 doi "https://doi.org/10.1038/s41416-018-0206-7" @default.
• W2886521817 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6162273" @default.
• W2886521817 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30072745" @default.
• W2886521817 hasPublicationYear "2018" @default.
• W2886521817 type Work @default.
• W2886521817 sameAs 2886521817 @default.
• W2886521817 citedByCount "11" @default.
• W2886521817 countsByYear W28865218172019 @default.
• W2886521817 countsByYear W28865218172020 @default.
• W2886521817 countsByYear W28865218172021 @default.
• W2886521817 countsByYear W28865218172022 @default.
• W2886521817 crossrefType "journal-article" @default.
• W2886521817 hasAuthorship W2886521817A5003303543 @default.
• W2886521817 hasAuthorship W2886521817A5004341345 @default.
• W2886521817 hasAuthorship W2886521817A5004971708 @default.
• W2886521817 hasAuthorship W2886521817A5010889533 @default.
• W2886521817 hasAuthorship W2886521817A5013129858 @default.
• W2886521817 hasAuthorship W2886521817A5013258133 @default.
• W2886521817 hasAuthorship W2886521817A5015274805 @default.
• W2886521817 hasAuthorship W2886521817A5023832239 @default.
• W2886521817 hasAuthorship W2886521817A5025092869 @default.
• W2886521817 hasAuthorship W2886521817A5025271372 @default.
• W2886521817 hasAuthorship W2886521817A5042172035 @default.
• W2886521817 hasAuthorship W2886521817A5045026176 @default.
• W2886521817 hasAuthorship W2886521817A5047438296 @default.
• W2886521817 hasAuthorship W2886521817A5050726729 @default.
• W2886521817 hasAuthorship W2886521817A5053997136 @default.
• W2886521817 hasAuthorship W2886521817A5054188737 @default.
• W2886521817 hasAuthorship W2886521817A5054335379 @default.
• W2886521817 hasAuthorship W2886521817A5070805573 @default.
• W2886521817 hasAuthorship W2886521817A5076136934 @default.
• W2886521817 hasAuthorship W2886521817A5084956582 @default.
• W2886521817 hasBestOaLocation W28865218171 @default.
• W2886521817 hasConcept C121608353 @default.
• W2886521817 hasConcept C126322002 @default.
• W2886521817 hasConcept C141071460 @default.
• W2886521817 hasConcept C146357865 @default.
• W2886521817 hasConcept C151730666 @default.
• W2886521817 hasConcept C197934379 @default.
• W2886521817 hasConcept C203092338 @default.
• W2886521817 hasConcept C207103383 @default.
• W2886521817 hasConcept C2776694085 @default.
• W2886521817 hasConcept C2778220009 @default.
• W2886521817 hasConcept C2778239845 @default.
• W2886521817 hasConcept C2908647359 @default.
• W2886521817 hasConcept C31760486 @default.
• W2886521817 hasConcept C44249647 @default.
• W2886521817 hasConcept C535046627 @default.
• W2886521817 hasConcept C71924100 @default.
• W2886521817 hasConcept C86803240 @default.
• W2886521817 hasConcept C90924648 @default.
• W2886521817 hasConcept C99454951 @default.
• W2886521817 hasConceptScore W2886521817C121608353 @default.
• W2886521817 hasConceptScore W2886521817C126322002 @default.

• next